US Food and Drug Administration approval of esketamine and brexanolone

Ioana A Cristea (1) , Florian Naudet (2)

1 Universitatea Babeş-Bolyai [Cluj-Napoca]
2 CIC - Centre d'Investigation Clinique [Rennes]

In March 2019, The USFood and Drug Administration (FDA) approved twonew antidepressants -esketamine for treatment-resistant depression (TRD)1and brexanolone for postpartum depression (PPD).

Domaines: Sciences du Vivant [q-bio]

Ioana A Cristea, Florian Naudet. US Food and Drug Administration approval of esketamine and brexanolone. The Lancet. Psychiatry, 2019, 6 (12), pp.975-977. ⟨10.1016/S2215-0366(19)30292-5⟩. ⟨hal-02363651⟩